Oppenheimer Issues a Buy Rating on United Therapeutics


In a report released today, Hartaj Singh from Oppenheimer assigned a Buy rating to United Therapeutics (NASDAQ: UTHR), with a price target of $180. The company’s shares opened today at $112.65.

Singh observed:

“We expect United Therapeutics (UTHR) to report a seasonally slow 1Q18 on 5/2. Historically, 1Q has been the slowest quarter for sales and earnings for UTHR, due to adjustment to sales for rebates, discounts, payments to patient assistance programs and Part D Donut hole coverage payments. The first quarter of every year tends to be seasonally slow for large-cap biotech companies broadly, accounting for ~23% of sales for the year (over the last 10 years). As such we adjust our numbers to reflect a seasonally weak sales/earnings quarter for UTHR (see exhibits below). We also applaud the purchase of SteadyMed (STDY), which potentially adds another pump to the Remodulin armamentarium and removes recent patent risk from an IPR loss. We stay bullish.”

According to TipRanks.com, Singh is a 5-star analyst with an average return of 20.4% and a 52.0% success rate. Singh covers the Healthcare sector, focusing on stocks such as Syndax Pharmaceuticals Inc, Strongbridge Biopharma Plc, and Catabasis Pharmaceuticals.

United Therapeutics has an analyst consensus of Hold, with a price target consensus of $137.50.

See today’s analyst top recommended stocks >>

The company has a one-year high of $152.55 and a one-year low of $101.99. Currently, United Therapeutics has an average volume of 431.1K.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

United Therapeutics Corp. engages in the development and commercialization of innovative products for patients with chronic and life-threatening diseases. It markets and sells commercial therapies to treat pulmonary arterial hypertension, high-risk neuroblastoma.

Stay Ahead of Everyone Else

Get The Latest Stock News Alerts